April 23, 2026 One thing I keep coming back to when I look at pharma launches over the last few years is this: We still talk about approval as if it’s the finish line. It isn’t. In today’s market, approval is the moment the real test begins. The companies that win are not just the ones with strong science. They’re the ones that can turn that science into access, uptake, and operational reality at scale. That’s the central pattern in your report: launches have become both more valuable and...

April 14, 2026 Over the last five years, pharmaceutical launches have become both more valuable and more fragile . On one end of the spectrum, we’ve seen true mega-launches generate billions in record time. On the other, we’ve watched high-profile approvals struggle under the weight of reimbursement delays, infrastructure gaps, evidence uncertainty, and operational bottlenecks. The lesson is clear: approval is no longer the finish line. It is the starting point of commercialization risk. ...

February 24, 2026 Pharmaceutical launches are unforgiving: early performance is hard to “make up” later, and complexity spans evidence generation, regulatory, supply, medical, access, and commercial execution. One large analysis summarized in a McKinsey launch compendium found that about two-thirds of 210 launches (new molecular entities, 2003–2009) missed pre-launch consensus first-year sales expectations, and that early underperformance often persisted. That dynamic is why “launch...